Your session is about to expire
← Back to Search
Cell Depletion Therapy for Blood Cancers
Study Summary
This trial studies the impact of stem cells on hematologic malignancies, using a new system for cell depletion and individualized dosing of medicine to improve outcomes.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My leukemia shows no minimal residual disease.My donor's genetic markers have been closely matched to mine.My lymphoma is currently in remission after a relapse.I can care for myself but may not be able to do active work or play.My leukemia is in a very early stage and not detectable by most tests.I agree to use birth control during my treatment.My blood cancer is in remission, pending approval from the study leader.I am younger than 25 years old.My leukemia shows no minimal residual disease.My organs are functioning well enough for a bone marrow transplant.I have been diagnosed with myelodysplasia.I have no active cancer other than the one specified, or I've been cancer-free from another type for over a year.My condition does not match the specific disease, organ, or infection requirements.I am not on any cancer treatments not listed in the study.My donor and their collection center agree to the cell collection process.My donor is a family member who matches at least half of my HLA markers.My donor has passed all required health screenings for transplant.My lymphoblastic lymphoma is currently in remission.My Burkitt's lymphoma/leukemia is currently in remission.My donor matches me closely in at least 9 out of 10 genetic markers.I am over 18 and can consent, or my guardian has consented for me.My leukemia is in a chronic, accelerated phase, or second chronic phase after a blast crisis.I do not have any active, untreated infections and have been treated for any fungal infections.I am willing to undergo a procedure to donate stem cells for my treatment.
- Group 1: Alpha/Beta T cell depletion (TCD) plus CD19+ depletion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Who qualifies to become a participant in this investigation?
"Candidates for this trial must have acute myeloid leukemia and be under the age of 25. The clinical study is currently seeking to enroll approximately 40 patients in total."
What is the capacity of participants in this trial?
"Affirmative. Clinicaltrials.gov's data reveals that this trial has been actively recruiting since May 1st, 2023 and was last revised on June 9th of the same year. The research requires 40 volunteers at a single site to participate."
Are there any current opportunities for participants in this clinical trial?
"Affirmative. According to clinicaltrials.gov, this research trial is presently searching for potential contributors. The original post date was on May 1st 2023 and the most recent modifications were made June 9th 2023. 40 participants are needed at one medical location."
Does this clinical trial admit participants of advanced age?
"This experiment stipulates that the youngest patient should be 0 years old, while the oldest can not surpass 25."
Share this study with friends
Copy Link
Messenger